Characterization of New Drugs
Safety Profile Before Marketing
Most drugs approved by FDA with average
of 1500 patient exposures
Some drugs have rare toxicity profiles
(bromfenac hepatotoxicity 1 in 20,000
patients)
For drugs with rare toxicity, more than
100,000 patients must be exposed to generate
a signal i.e. after drug is marketed